Search results
Results from the WOW.Com Content Network
Binding of the neurotransmitter 5-hydroxytryptamine to the 5-HT 3 receptor opens the channel, which, in turn, leads to an excitatory response in neurons. The rapidly activating, desensitizing, inward current is predominantly carried by sodium and potassium ions. [2] 5-HT 3 receptors have a negligible permeability to anions. [1]
Finasteride was the first 5-ARI to be introduced for medical use. [43] It was marketed for the treatment of BPH in 1992 and was subsequently approved for the treatment of pattern hair loss in 1997. [43] Epristeride was the second 5-ARI to be introduced and was marketed for the treatment of BPH in China in 2000. [14]